Cilengitide sensitivity is predicted by overall integrin expression in breast cancer
Integrin inhibitors are appealing candidates to pursue as anti-cancer drugs because they are generally well-tolerated, but their efficacy is mixed, possibly due to the absence of predictive markers. Cilengitide induces death in breast cancer cells with low integrin abundance, where complementary ECM promotes survival. Thus, integrin inhibition in breast cancer warrants further study.
Authors
- Benjamin Marks (ORCID: https://orcid.org/0000-0003-0462-4040)
- Ioannis K. Zervantonakis (ORCID: https://orcid.org/0000-0003-2386-9553)
- Chris Sander (ORCID: https://orcid.org/0000-0001-6059-6270)
- Jingyou Yu (ORCID: https://orcid.org/0000-0002-0775-6623)
- Aylin Z. Henstridge (ORCID: https://orcid.org/0000-0003-1517-8306)
- Augustin Luna (ORCID: https://orcid.org/0000-0001-5709-371X)
- Nomeda Girnius (ORCID: https://orcid.org/0000-0002-7267-5950)
- G. Kenneth Gray (ORCID: https://orcid.org/0000-0003-4969-670X)
Institutions
- Harvard University (US)
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Center for Systems Biology (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s13058-024-01942-2
- Citations
- 9
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- National Institute of General Medical Sciences
- U.S. National Library of Medicine